VGTI Florida to Collaborate with TapImmune to Advance Targeted Breast and Ovarian Cancer Vaccines into Phase II Clinical Trials

VGTI Florida to coordinate cancer study design and trial sites selection November 18, 2014 The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, today announced a new collaborative research agreement with TapImmune, Inc., forming a partnership to advance TapImmune’s proprietary, targeted cancer vaccines into mid-stage, Phase II human clinical trials for the treatment …

TapImmune, Inc. Announces $2 Million Registered Direct Offering

  August 11th, 2014 TapImmune, Inc. (the “Company”), (OTCQB:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a price of $1.06 per share. In addition, the Company will issue to the investor warrants to purchase up to 1,886,793 shares of common stock. The …

TapImmune’s New Clinical Trial in Advanced Stage Ovarian Cancer Expands the Use of Folate Receptor Alpha Peptide Antigens

August 7th, 2014 TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN. The folate receptor alpha peptides being used in this study are the same ones …

TapImmune Prevails in Legal Dispute with Michael Gardner

International Arbitration Tribunal Finds in Favor of TapImmune Inc., and Awards the Company $196,204 in Damages July 24th, 2014 TapImmune Inc. (OTCQB:TPIV), announces successful outcome of proceedings against Michael Gardner after almost 2 years of litigation. The International Center for Dispute Resolution International Arbitration Tribunal has found that Mr. Gardner made numerous false representations, did not fully provide the services …

TapImmune Announces the Filing of New Intellectual Property for its Platform Expression System Polystart

New Technology Significantly Enhances the Presentation of Desired Peptides on the Surface of Cells for Targeting to the Immune System March 20, 2014 TapImmune Inc., a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has filed a new patent application for a novel technology platform designed to enhance …